BusinessNeuralstem Announces Last Subject Enrolled in Phase 2 Trial with NSI-189 for Major Depressive DisorderBy Nasdaq OMXFeb 16, 2017, 12:02 PM UTC
BusinessNeuralstem Announces the Closing of $20 Million Strategic Investment from Tianjin Pharmaceutical Group International Holdings Co., LTD.By Nasdaq OMXDec 12, 2016, 12:38 PM UTC
